Companies › SynAct Pharma Aps
1 active drug program in 3 registered trials: 3 Phase 2; Genitourinary, Immunology, Infectious disease; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AP1189 Toll-like receptor 7 (TLR7) agonist | – | Phase 2 | Rheumatoid Arthritis (RA); Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy; Respiratory Viral Infection | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06671054 | AP1189 | Phase 2 | Rheumatoid Arthritis (RA) | Immunology | Dec 2025 |
| NCT04456816 | AP1189 | Phase 2 | Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy | Genitourinary | Jun 2026 |
| NCT07633288 | AP1189 | Phase 2 | Respiratory Viral Infection | Infectious disease | Aug 2027 |
No annotated target.
–
IR INNOVATE RESEARCH PRIVATE Shanghai Longwood Biopharmaceuticals Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Hyundai Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.